Source BioScience

The increase was driven by a 17 percent jump in revenues for the firm's laboratory services division, offset by lower product sales.

The genomic products and services firm said that no assets or personnel will be transferred, but it will license its analysis software to Source BioScience.

The firm's lab services division saw 9 percent revenue growth, while its product sales fell 8 percent.

NEW YORK (GenomeWeb) – Source BioScience today reported that its first-half 2014 revenues increased 46 percent year over year driven by its diagnostics services business.

Lab7 Systems has released a beta version of its next-generation sequencing data workflow management software platform, available for download to early-access users from the company's website. The company is planning updates to the software every four to six weeks.

A group at the University of Oxford has begun offering a sequencing-based cancer test that uses Life Technologies' Ion Torrent PGM — the first sequencing-based product developed under the UK's Stratified Medicine Program.

Source BioScience, a UK-based genomic service provider, is focusing its R&D resources on informatics development in an effort to expand its business into the global market.

Source BioScience's DNA sequencing services business has grown by 60 percent year over year, driven by its overnight services, the UK-based company reported this week in its half-year 2012 earnings report.

NEW YORK (GenomeWeb News) – Source BioScience reported today an 11 percent increase year over year in revenues for the first half of 2012.

NEW YORK (GenomeWeb News) – Source BioScience said this week that it has extended its next-generation sequencing services to include the Illumina MiSeq platform.

Pages

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.